Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of EASYEF in Acute Wound (Skin Graft Donor Site)
NCT05335720Completed
- Sponsor
- Daewoong Infion
- Start
- Jul 2019
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of nepidermin in split-thickness skin graft donor site wound (2 cohorts), sponsored by Daewoong Infion. Primary endpoint: Comparison of the wound healing time of each skin graft donor site at 14 days. Started Jul 2019; status: completed.
02
Drugs
nepidermin
03
Conditions
split-thickness skin graft donor site wound
Beyond the preview
Go deeper on NCT05335720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335720.